Benzinga · Feb 11, 2026
GR
NASDAQ · GRDX
GridAI Technologies Corp. Common Stock
Healthcare · Biotechnology
$3.29
Up+$0.76 (+23.10%)
Updated Aug 13, 2026, 6:33 PM
SID Score
4.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.61M
- P/E ratio
- -0.33
- Dividend yield
- 0.00%
- 52-week range
- $1.87 – $6.93
- Volume
- 181.69K
- Avg. volume
- 218.58K
Price performance
GRDX price history
1M range · 21 trading sessions · Daily adjusted prices
GRDX closed at $3.29 after 21 trading sessions, down 18.77% for the selected period.
- Last close
- $3.29
- Period change
- -18.77%
- Period low
- $2.60
- Period high
- $4.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 12, 2026 | $3.24 | $3.55 | $3.06 | $3.29 | 181.69K |
| Aug 11, 2026 | $3.015 | $3.23 | $2.97 | $3.15 | 157.55K |
| Aug 10, 2026 | $2.78 | $3.08 | $2.69 | $3.01 | 40.68K |
| Aug 7, 2026 | $2.7148 | $2.8799 | $2.7148 | $2.74 | 37.97K |
| Aug 6, 2026 | $2.81 | $2.88 | $2.72 | $2.88 | 38.09K |
| Aug 5, 2026 | $2.71 | $3.03 | $2.7096 | $2.77 | 215.02K |
| Aug 4, 2026 | $2.91 | $3.05 | $2.73 | $2.75 | 55.55K |
| Aug 3, 2026 | $2.96 | $3.09 | $2.82 | $2.91 | 24.99K |
| Jul 31, 2026 | $3.074 | $3.074 | $2.8641 | $2.90 | 62.79K |
| Jul 30, 2026 | $2.56 | $3.21 | $2.56 | $3.05 | 124.01K |
| Jul 29, 2026 | $2.90 | $2.965 | $2.60 | $2.60 | 68.36K |
| Jul 28, 2026 | $3.11 | $3.11 | $2.82 | $2.99 | 48.39K |
| Jul 27, 2026 | $3.03 | $3.175 | $2.9506 | $3.15 | 29.37K |
| Jul 24, 2026 | $3.42 | $3.42 | $2.86 | $3.04 | 256.93K |
| Jul 23, 2026 | $3.31 | $3.42 | $3.10 | $3.35 | 17.9K |
| Jul 22, 2026 | $3.41 | $3.63 | $3.33 | $3.42 | 23.48K |
| Jul 21, 2026 | $3.33 | $3.84 | $3.32 | $3.54 | 77.04K |
| Jul 20, 2026 | $3.82 | $3.82 | $3.19 | $3.20 | 22.69K |
| Jul 17, 2026 | $3.80 | $4.04 | $3.62 | $3.82 | 33.82K |
| Jul 16, 2026 | $4.09 | $4.09 | $3.785 | $3.81 | 11.49K |
| Jul 15, 2026 | $3.90 | $4.24 | $3.73 | $4.05 | 70.05K |
Latest GRDX news
The latest Smart Investors Daily articles mentioning GRDX.
Stock researchCompany · Overview
GRDX research
Overview
Company profile and research snapshot.
Company profile
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Feb 4, 2026
GridAI Technologies Appoints EnerNOC Co-Founder Tim Healy As Executive Chairman Of Grid AI Corp
Yahoo · Jan 14, 2026
GridAI Technologies (GRDX) Positions Itself at the Operating Layer of a Continuously Managed Electric Grid
LOS ANGELES, CA - January 14, 2026 (NEWMEDIAWIRE) - GridAI Technologies (NASDAQ: GRDX) is aligning its platform with a structural shift in how the electric grid is operated as accelerating AI workloads, electrification, and distributed energy resourc...
Yahoo · Jan 14, 2026
GridAI and the New Operating Reality of the Electric Grid
BOCA RATON, FL / ACCESS Newswire / January 14, 2026 / For decades, managing the electric grid was largely a planning exercise. Operators forecast demand, built capacity, and adjusted slowly as conditions evolved. That model worked in an era when consumption ...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
